Nav: Home

Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug

March 23, 2017

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified the first genetic mechanisms conferring acquired resistance to a promising group of targeted cancer drugs. In a paper appearing in the March issue of Cancer Discovery, the researchers describe finding novel resistance mechanisms in three patients receiving fibroblast growth factor receptor (FGFR) inhibitor treatment for a type of liver cancer. While many patients show impressive responses to this treatment, the appearance of new drug-resistant mutations in the FGFR gene as tumors progress- and even several different mutations within samples from individual patients - suggests the need for drugs that block multiple pathways to avoid the resumption of tumor progression.

"FGFR represents an important therapeutic target in many cancers," says lead author Lipika Goyal, MD, MPhil, of the MGH Cancer Center. "Our findings may inform future strategies for detecting resistance mechanisms and inducing more durable responses in FGFR2 fusion-positive intrahepatic cholangiocarcinoma and possibly other cancers in which the FGFR pathway is being explored as a therapeutic target."

Cancers driven by mutations that activate FGFR include certain tumors of the lung, breast, stomach and bladder. From 10 to 20 percent of cases of intrahepatic cholangiocarcinoma (ICC) - the second most common tumor originating in the liver - are thought to be driven by FGFR2 fusion mutations. An FGFR inhibitor called BGJ398 is currently in a phase 2 clinical trial for treatment of advanced ICC patients whose FGFR-driven cancers progressed after chemotherapy, and while preliminary data from the trial reported a significant response to treatment, as with most targeted therapies, resistance inevitably develops.

The MGH team analyzed samples from three patients with FGFR2 fusion-positive ICC enrolled in the BGJ398 trial for whom treatment led to a 30 to 50 percent tumor reduction, followed by disease progression after four to eight months. Analysis of cell-free DNA (cfDNA) from blood samples taken before BGJ398 treatment and after tumor progression revealed that one to five new FGFR2 kinase domain mutations had developed in each patient. A common mutation that emerged in all three patients was FGFR2 V564F, a gatekeeper mutation which interferes with the binding of BGJ398 to the FGFR. The other mutations altered the conformation of FGFR2, leading to continuous signaling through the pathway.

Rapid autopsy samples from one patient who died after having disease progression on BGJ398 treatment revealed that different metastases harbored distinct FGFR2 mutations, thus demonstrating that multiple different mechanisms can confer resistance in individual patients. Treating BGJ398-resistant cell lines with several other FGFR inhibitors showed that other structurally distinct drugs in the same class may be able to overcome FGFR2 resistance mutations.

"As seen with the development of resistance to other targeted treatment drugs, the mechanisms we identified are heterogeneous, and different therapeutic approaches may be necessary to overcome those resistance mechanisms," says senior and co-corresponding author Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at the MGH Cancer Center. "In addition to helping us understand why patients developed tumor progression within months of beginning a rationally chosen targeted therapy, our findings also suggest that tumor biopsies may underestimate resistance mechanisms. Repeat analysis of cfDNA may provide a more comprehensive picture of the mechanisms at play."
-end-
Goyal is an instructor and Zhu is a professor of Medicine at Harvard Medical School. Additional co-authors of the Cancer Discovery paper include Ryan Corcoran, MD, PhD, Supriya Saha, MD, PhD, Leah Liu, PhD, Dejan Juric, MD, and Nabeel Bardeesy, PhD, of the MGH Cancer Center. Funding for this research was provided by the Cholangiocarcinoma Foundation, TargetCancer Foundation, the MGH Executive Committee on Research Fund for Medical Discovery Award, the National Institutes of Health/National Cancer Institute Gastrointestinal Cancer SPORE, The V Foundation for Cancer Research, and the Jonathan Kraft Translational Award, among others.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Liver Cancer Articles:

Report looks at liver cancer, fastest-growing cause of cancer deaths in US
A new report provides an overview of incidence, mortality, and survival rates and trends for liver cancer, a cancer for which death rates have doubled in the United States since the mid-1980s
The IT-LIVER European consortium unveils new TGF-beta functions in liver cancer
Recent research results from the European consortium IT-Liver provide a better understanding of the role of the TGF-beta cytokine in liver cancer.
A novel molecular link between cholesterol, inflammation and liver cancer
Hepatocellular carcinoma (HCC) is a deadly disease with no effective cure that develops in the context of liver diseases associated with chronic inflammation.
One more piece in the puzzle of liver cancer identified
Manuela Baccarini and her team at the Max F. Perutz Laboratories (MFPL) of the University of Vienna and Medical University of Vienna are one step closer to unraveling the mechanisms behind liver cancer.
New approach to liver transplantation: Using a damaged liver to replace a dying liver
There's new hope for patients with liver disease who are waiting for a donor liver to become available for transplantation.
Damage to tiny liver protein function leads to heart disease, fatty liver
A UCF College of Medicine researcher has identified for the first time a tiny liver protein that when disrupted can lead to the nation's top killer -- cardiovascular disease -- as well as fatty liver disease, a precursor to cancer.
Targeted treatment for liver cancer under way
Researchers at the University of Eastern Finland and Eberhard Karls Universität Tübingen have discovered a new molecular mechanism that can be used to inhibit the growth of hepatocellular carcinoma, which is the most common liver cancer.
Transplanted liver cells protect against liver failure after massive hepatectomy surgery
Because liver failure often occurs after an extensive hepatectomy, researchers using animal models investigated safer ways to transplant liver cells post-extensive hepatectomy found that rather than transplanting cells into the liver portal vein, transplantation into an extra-hepatic site, such as the intra-mesentery, a fold of membranous tissue on the posterior wall of the abdominal cavity attached to the intestinal tract, can help protect against post-operative liver failure and aid in survival of the remaining liver.
Scientists root out the 'bad seeds' of liver cancer
Researchers have found the 'bad seeds' of liver cancer and believe they could one day reprogram them to remain responsive to cancer treatment, a new USC study has found.
Retroviral RNA may play a part in liver cancer
Researchers have found that retroviral long-terminal-repeat (LTR) promoters -- a type of repetitive element that are widely distributed in the human genome -- are highly activated in hepatocellular carcinomas, the most common type of liver cancer.

Related Liver Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.